NT-proANP and NT-proBNP for diagnosing cardiac diseases

US7608418B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Georg Hess · Mainz, DE
• Andrea Horsch · Luzern, CH

Key dates

• Filing date: Nov 27, 2007
• Grant date: Oct 27, 2009
• Expiry date: Feb 5, 2028

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/325
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Described are methods for diagnosing a cardiac disease, particularly an acute cardiac event, in a patient presenting with symptoms of acute cardiac decompensation, comprising the steps of (a) measuring, typically in vitro, the level of NT-proBNP (N-terminal brain natriuretic peptide) or a variant thereof in a sample from the patient, (b) measuring, typically in vitro, the level of NIT-proANP (N-terminal atrial natriuretic peptide) or a variant thereof in a sample from the patient, (c) combining the information of the measured levels of NT-proANP and NT-proBNP, wherein an increased level of NT-proANP in presence of a non-increased or weakly increased level of NT-proBNP indicates the presence of an acute cardiac event, or wherein an increased level of NT-proANP in presence of a highly increased level of NT-proBNP indicates the presence of a chronic cardiac disease. The methods also allow distinguishing an acute cardiac event from decompensation of a chronic cardiac disease. Described also are corresponding kits and to methods of treatment of cardiac diseases.